Omniab, Inc. ( (OABI) ) has released its Q3 earnings. Here is a breakdown of the information Omniab, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
OmniAb, Inc. is a biotechnology company that licenses advanced discovery research technology to pharmaceutical and biotech companies, focusing on creating and screening diverse antibody repertoires for drug development.
In its third-quarter 2025 financial report, OmniAb highlighted its strategic initiatives and the expansion of its technology platform, despite a decrease in revenue compared to the previous year. The company also announced the upcoming launch of its new OmniUltra technology, which is expected to open new business opportunities.
The company’s financial performance showed a revenue of $2.2 million for the third quarter of 2025, a decrease from $4.2 million in the same period of 2024, primarily due to lower milestone and service revenues. Research and development expenses decreased to $10.4 million, while general and administrative expenses were slightly reduced to $6.8 million. OmniAb reported a net loss of $16.5 million for the quarter. For the nine months ended September 30, 2025, revenue was $10.3 million, down from $15.6 million in 2024, with a net loss of $50.6 million.
OmniAb’s business highlights include new license agreements and the expansion of its intellectual property portfolio with a new U.S. patent for its OmniUltra technology. The company also reported progress in various partnered programs, including clinical developments and collaborations with institutions like the Dana-Farber Cancer Institute.
Looking ahead, OmniAb expects its 2025 revenue to be between $18 million and $22 million, with operating expenses ranging from $82 million to $86 million. The company anticipates ending the year with cash between $52 million and $56 million, reflecting a cautious but optimistic outlook on its financial and operational performance.